Table 1

Patient and treatment summary
Patient/age	Diagnosis	Grade*	Implant site	Margins	CMT	Group*	HDRBT (Gy)	EBRT (Gy)	Local failure	Distant failure	DFS (mo)

female/9	RMSE	III	Head neck	Negative	Yes	I	18	41.4			159
female/16	Synovial sarcoma	III	extremity	Negative	None	I	24	None			19
Female/2	ASPS	II	Extremity	Negative	Yes	I	24	None			21
Female/14	Synovial sarcoma	II	Extremity Hand	Positive	None	II	24	41.4		Lung	45
Male/5	Synovial sarcoma	II	Head neck	Negative	Yes	I	24	None			79
Female/12	ASPS	III	Extremity	Negative	None	I	18	30.6			29
Female/2	RMSE	II	Pelvic	negative	Yes	I	24	None			54
Male/4	ASPS	II	Extremity	Positive	Yes	II	24	None			143
female/1	ASPS	III	Extremity	Positive	Yes	II	30	None		Lung	18
Male/2	fibrosarcoma	II	Pelvic	Negative	Yes	I	40	None			83
Female/11	Synovia sarcomal	III	Extremity	Positive	Yes	II	24	50			141
Female/9	RMSE	III	Head Neck	Positive	Yes	III	18	43.2			65
Female/12	RMSE	III	Head Neck	positive	Yes	III	18	45			94
Male/2	ASPS	II	Pelvic	Negative	Yes	I	21	None			12
Male/9	Synovial sarcoma	II	Extremity	Negative	Yes	I	30	None			114
Female/12	RMS pleomorfic	II	Extremity	Negative	None	I	21	None			80
Female/3	Sarcoma indiferency	III	Extremity	Negative	Yes	I	21	41.4		Lung	38
female/16	ASPS	III	Extremity	Positive	Yes	III	24	50.0	yes	NCS	18

*Intergroup Rhabdomyosarcoma Study (IRS) staging used for both rhabdomyosarcomas and nonrhabdomyosarcomas. ASPS= soft tissue sarcoma alveolar, RMSE= Rhabdomyosarcoma embryonary
Viani et al. Radiation Oncology 2008 3:9 doi:10.1186/1748-717X-3-9